NCHR Testimony at FDA on Gastric LAP-BAND

December 3, 2010. In their newly proposed label, Allergan indicated a “caution” (not a warning) for patients with autoimmune diseases or symptoms, and did NOT mention a family history of those conditions.

Read More »

NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin

September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.

Read More »

NCHR Testimony on Avastin

July 20, 2010. It is clear that the benefits do not outweigh the risks and that the indication for treatment of metastic breast cancer should be REMOVED from the Avastin label.

Read More »